{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-058967","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2026-05-12T10:45:26+00:00","discovered_at":"2026-05-12T10:50:00.272604+00:00","generated_at":"2026-05-12T10:50:54.550238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProMIS Neurosciences Q1 net loss $8.2M; PRECISE-AD interim analysis expected early Q3 2026","bullets":["Net loss of $8.2M for Q1 2026, vs $7.3M in Q1 2025; cash & equivalents $63.8M as of March 31.","Closed $75.5M PIPE in Feb 2026; up to $100M additional from warrant exercises; funds operations through 2027.","PRECISE-AD Phase 1b fully enrolled (144 participants); blinded 6-month interim analysis anticipated early Q3 2026.","Unblinded 12-month top-line data expected early 2027; subcutaneous formulation development accelerated.","Lead candidate PMN310 selectively targets toxic amyloid-beta oligomers, aiming to improve safety vs plaque-directed antibodies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058967","json":"https://secwatch.observer/filing/0001104659-26-058967.json","markdown":"https://secwatch.observer/filing/0001104659-26-058967.md","text":"https://secwatch.observer/filing/0001104659-26-058967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/0001104659-26-058967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T10:50:54.550238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40353608f85cb44467a0c7b7e7bbdd0f69349aac","claim":"ProMIS Neurosciences Inc. reported financial results for quarter ended March 31, 2026.","evidence_excerpt":"reporting its financial condition and financial results as of and for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/0001104659-26-058967-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}